据近期出版的美国《国立癌症研究所杂志》报道,Raf激酶抑制蛋白(RKIP)似乎可以抑制前列腺癌细胞的转移。该研究发现有可能导致产生新的癌症治疗干预手段。美国密歇根大学的Evan T.Keller博士及其同事在此前的研究中证实,与转移的前列腺癌细胞相比,RKIP在非转移的前列腺癌细胞中的水平更高。尽管如此,仍然缺乏RKIP可阻止癌转移的直接证据。在目前进行的试验中,研究 According to a recently published report from the National Cancer Institute, Raf kinase inhibitor (RKIP) appears to inhibit the metastasis of prostate cancer cells. The study found that it may lead to new cancer treatment interventions. Dr. Evan T. Keller, University of Michigan, and colleagues in previous studies confirmed that RKIP is more highly expressed in non-metastatic prostate cancer cells than metastatic prostate cancer cells. In spite of this, there is still a lack of direct evidence that RKIP can prevent cancer metastasis. In the current experiment, the study